- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Evolus and Oramed Pharmaceuticals Compared
Two small-cap medical companies vie for investor attention
Apr. 13, 2026 at 4:22am
Got story updates? Submit your updates here. ›
The technical complexity of the medical device and pharmaceutical industries is on full display in this cinematic close-up of the machinery powering innovative therapies.Newport Beach TodayEvolus (NASDAQ:EOLS) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but analysts believe Evolus has stronger growth potential based on its consensus rating and upside target price.
Why it matters
The comparison highlights the competitive landscape in the cash-pay aesthetic and diabetes treatment markets, where these two companies are vying for investor capital and market share.
The details
Evolus focuses on delivering aesthetic products like the Jeuveau botulinum toxin treatment, while Oramed is developing oral insulin and diabetes therapies. The companies differ in their market capitalization, institutional ownership, and financial metrics like profitability and return on equity.
- Evolus was incorporated in 2012 and is headquartered in Newport Beach, California.
- Oramed Pharmaceuticals was incorporated in 2002 and is headquartered in New York.
The players
Evolus, Inc.
A performance beauty company that focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.
Oramed Pharmaceuticals Inc.
A pharmaceutical company that engages in the research and development of solutions for the treatment of diabetes and the use of orally ingestible capsules for delivery of polypeptides.
The takeaway
The comparison between Evolus and Oramed Pharmaceuticals highlights the competitive dynamics in the medical aesthetics and diabetes treatment markets, where smaller companies are vying for investor attention and market share through innovative product pipelines and financial performance.
